Soleno Therapeutics announced updates to its Board of Directors. Dawn Carter Bir, a seasoned biotechnology executive with over 30 years of industry executive leadership and strategic experience, has been appointed to Soleno’s Board of Directors. In addition, Board Chairman Ernest Mario, Ph.D. is stepping down from the Board due to health reasons. Current Board member Matthew Pauls, J.D., M.B.A. is assuming the role of Lead Independent Director. Bir recently served as Executive Vice President, member of the core executive team.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Announces Updates to its Board of Directors
- Soleno Therapeutics price target raised to $65 from $59 at Oppenheimer
- Is SLNO a Buy, Before Earnings?
- These Stock Winners Are ‘Strong Buys’ With More Room Left to Run
- Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome